LIMNW Liminatus Pharma, Inc. - Warrants
NASDAQ · View on SEC EDGAR ↗ close Sep 30, 2026 10-K/10-Q Aug 14, 2026
$0.05
· of 52w range
· above low
· to high
$0.0452w low
$0.0952w high
Market Cap (MRQ)
$3M
EPS
$-0.43
your badges
52W Range
$0–$0
Analyst Rating
·
Price Target
·
P/E
·
ROE
109.6%
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
LIMNW Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$0.05
Market Cap (MRQ)
$3M
EPS
$-0.43
ROE
109.6%
Debt/Equity (MRQ)
4.8
52W Range
$0–$0
LIMNW Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
EPS$-0.432024-12-31 → 2025-12-31
Free Cash Flow$-10M2025-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | LIMNW | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/B (MRQ) | 9.2 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | LIMNW | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| ROA | -344.7% | · | · | · | |
| ROE | 109.6% | · | · | · |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | LIMNW | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | 4.8 | · | · | · | |
| Current Ratio (MRQ) | 1.1 | · | · | · | |
| Quick Ratio | 0.0 | · | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| R&D Expense | · | $3M | |
| SG&A Expense | $3M | $644.6K | |
| Operating Expenses | $3M | $3M | |
| Operating Income | $-3M | $-3M | |
| Interest Income | $76.6K | $122.5K | |
| Other Non-op | $-7M | $-216.4K | |
| Net Income | $-10M | $-4M | |
| EPS (Basic) | $-0.43 | $-0.20 | |
| EPS (Diluted) | $-0.43 | $-0.20 | |
| Shares (Basic) | 23,753,561 | 17,500,000 | |
| Shares (Diluted) | 23,753,561 | 17,500,000 | |
| EBITDA | $-3M | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Cash & Equivalents | $337.7K | $56.3K | |
| Prepaid Expense | $162.9K | $155.5K | |
| Current Assets | $500.6K | $5M | |
| PP&E (Net) | $12.2K | $941 | |
| Total Assets | $512.8K | $5M | |
| Accounts Payable | $582.2K | $1M | |
| Accrued Liabilities | · | $805 | |
| Short-term Debt | $1M | $20M | |
| Current Liabilities | $10M | $25M | |
| Total Liabilities | $10M | $25M | |
| Total Debt | $1M | · | |
| Common Stock | $2.7K | $1.8K | |
| Paid-in Capital | $29M | $9M | |
| Retained Earnings | $-39M | $-29M | |
| Stockholders' Equity | $-10M | $-19M | |
| Liabilities + Equity | $512.8K | $5M | |
| Shares Outstanding | 27,064,633 | 17,500,000 |
Cash Flow
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Operating Cash Flow | $-10M | $-1M | |
| CapEx | $13.1K | · | |
| Investing Cash Flow | $-788.1K | $-3M | |
| Financing Cash Flow | $11M | $4M | |
| Net Change in Cash | $281.3K | $-378.1K | |
| Taxes Paid | $0 | $0 | |
| Free Cash Flow | $-10M | · |
Profitability
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| ROA | -344.7% | · | |
| ROE | 109.6% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Current Ratio | 0.0 | · | |
| Quick Ratio | 0.0 | · | |
| Debt / Equity | -0.1 | · |
Per Share
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Book Value / Share | $-0.36 | · | |
| Cash Flow / Share | $-0.42 | · | |
| Cash / Share | $0.01 | · | |
| EPS (TTM) | $-0.43 | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Net Income TTM | $-10M | · |
Income Statement
| Metric | Trend | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $600.0K | · | · | · | · | $0 | $357.1K | $714.1K | · | |
| SG&A Expense | $778.9K | $884.2K | $701.2K | $1M | · | $167.1K | $186.1K | $195.1K | · | |
| Operating Expenses | $1M | $884.2K | $701.2K | $1M | · | $167.1K | $543.1K | $909.2K | · | |
| Operating Income | $-1M | $-1M | $-701.2K | $-1M | $-255 | $-2M | $-543.1K | $-909.2K | $-247 | |
| Interest Income | · | $0 | $0 | $24.4K | · | $43.5K | $34.5K | $25.2K | · | |
| Other Non-op | $-28.4K | $-7M | $-1M | $1M | · | $-62.7K | $-58.2K | $-52.0K | · | |
| Net Income | $-1M | $-8M | $-2M | $113.3K | $-327.5K | $-229.8K | $-601.4K | $-961.2K | $-2M | |
| EPS (Basic) | $-0.03 | $2.19 | $-0.07 | $0.00 | $-2.55 | $2.35 | $-0.03 | $-0.05 | $-2.47 | |
| EPS (Diluted) | $-0.03 | $2.19 | $-0.07 | $0.00 | $-2.55 | $2.35 | $-0.03 | $-0.05 | $-2.47 | |
| Shares (Basic) | 48,398,314 | · | 27,007,568 | 23,301,178 | 100 | · | 17,500,000 | 17,500,000 | 100 | |
| Shares (Diluted) | 48,398,314 | · | 27,007,568 | 23,301,178 | 100 | · | 17,500,000 | 17,500,000 | 100 | |
| EBITDA | $-1M | · | $-701.2K | $-1M | $-255 | · | · | · | · |
Balance Sheet
| Metric | Trend | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3M | $337.7K | $724.5K | $1M | · | $56.3K | · | · | · | |
| Prepaid Expense | $375.4K | $162.9K | $478.9K | $444.1K | · | $155.5K | · | · | · | |
| Current Assets | $3M | $500.6K | $1M | $2M | · | $5M | · | · | · | |
| PP&E (Net) | $11.2K | $12.2K | $12.8K | $198 | · | $941 | · | · | · | |
| Total Assets | $3M | $512.8K | $1M | $2M | · | $5M | · | · | · | |
| Accounts Payable | $655.1K | $582.2K | $559.2K | $431.9K | · | $1M | · | · | · | |
| Accrued Liabilities | · | · | · | · | $1.1K | · | · | · | · | |
| Short-term Debt | $1M | $1M | $1M | $1M | · | $20M | · | · | · | |
| Current Liabilities | $3M | $10M | $3M | $11M | · | $25M | · | · | · | |
| Total Liabilities | $3M | $10M | $3M | $11M | $1.1K | $25M | · | · | · | |
| Total Debt | $1M | · | $1M | $1M | · | · | · | · | · | |
| Common Stock | $5.6K | $2.7K | $2.7K | $2.6K | $0 | $1.8K | · | · | · | |
| Paid-in Capital | $42M | $29M | $29M | $20M | $10 | $9M | · | · | · | |
| Retained Earnings | $-41M | $-39M | $-31M | $-29M | $-1.1K | $-29M | · | · | · | |
| Stockholders' Equity | $300.6K | $-10M | $-2M | $-9M | $-1.1K | $-19M | · | · | · | |
| Liabilities + Equity | $3M | $512.8K | $1M | $2M | · | $5M | · | · | · | |
| Shares Outstanding | 55,971,633 | 27,064,633 | 27,064,633 | 26,014,633 | · | 17,500,000 | · | · | · |
Cash Flow
| Metric | Trend | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-970.0K | $-386.8K | $-600.6K | $-9M | $0 | $-140.7K | $-206.1K | $-1M | $0 | |
| CapEx | · | $0 | · | · | · | · | · | · | · | |
| Investing Cash Flow | · | $0 | $-13.1K | $-200.0K | · | $-550.0K | $-800.0K | · | · | |
| Financing Cash Flow | $2M | $0 | $0 | $10M | · | $700.0K | $1M | · | · | |
| Net Change in Cash | $1M | $-386.8K | $-613.7K | $1M | $0 | $9.3K | $12.9K | $-400.3K | $0 |
Profitability
| Metric | Trend | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -53.0% | · | -271.6% | 11.9% | · | · | · | · | · | |
| ROE | 33.1% | · | 221.6% | -2.6% | 48.1% | · | · | · | · |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.1 | · | 0.4 | 0.2 | · | · | · | · | · | |
| Quick Ratio | 1.0 | · | 0.3 | 0.1 | · | · | · | · | · | |
| Debt / Equity | 4.8 | · | -0.9 | -0.2 | · | · | · | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.01 | · | $-0.06 | $-0.34 | · | · | · | · | · | |
| Cash Flow / Share | · | · | · | · | $0.00 | · | · | · | · | |
| Cash / Share | $0.05 | · | $0.03 | $0.05 | · | · | · | · | · | |
| EPS (TTM) | $2.06 | · | $2.26 | $2.30 | $2.25 | · | · | · | · |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-13M | · | $-2M | $-1M | $-2M | · | · | · | · | |
| Market Cap | $3M | · | · | · | · | · | · | · | · | |
| Enterprise Value | $2M | · | · | · | · | · | · | · | · | |
| P/E | 0.0 | · | · | · | · | · | · | · | · | |
| P/B | 11.2 | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 11.2 | · | · | · | · | · | · | · | · | |
| Earnings Yield | 3433.3% | · | · | · | · | · | · | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Income | $-10M | $-4M |
| Diluted EPS | $-0.43 | $-0.20 |
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Debt / Equity | -0.1 | · |
| Current Ratio | 0.0 | · |
| Quick Ratio | 0.0 | · |
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | $-10M | · |
Institutional owners (13F) 25 filers · $289K total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
25
Value held
$289K
New positions
2
Exited positions
1
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 2 (+1 vs prior Q) | 1 (-3 vs prior Q) | 0 (-1 vs prior Q) | 3 (+1 vs prior Q) | -15K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| CLEAR STREET LLC | $193,234 | 805,477 | 66.88% | Shares |
| ARISTEIA CAPITAL, L.L.C. | $16,279 | 319,510 | 5.63% | Shares |
| Linden Advisors LP | $13,678 | 268,199 | 4.73% | Shares |
| Saba Capital Management, L.P. | $11,910 | 233,761 | 4.12% | Shares |
| MOORE CAPITAL MANAGEMENT, LP | $9,375 | 125,000 | 3.24% | Shares |
| MMCAP International Inc. SPC | $8,381 | 111,745 | 2.90% | Shares |
| Polar Asset Management Partners Inc. | $6,257 | 122,688 | 2.17% | Shares |
| MILLENNIUM MANAGEMENT LLC | $5,296 | 70,616 | 1.83% | Call option |
| D. E. Shaw & Co., Inc. | $2,934 | 83,353 | 1.02% | Shares |
| TORONTO DOMINION BANK | $2,633 | 35,100 | 0.91% | Shares |
| Cubist Systematic Strategies, LLC | $2,334 | 15,778 | 0.81% | Shares |
| LMR Partners LLP | $2,247 | 29,961 | 0.78% | Shares |
| Arena Capital Advisors, LLC- CA | $2,187 | 29,166 | 0.76% | Shares |
| Blue Owl Capital Holdings LP | $2,000 | 50,000 | 0.69% | Shares |
| Periscope Capital Inc. | $1,980 | 30,000 | 0.69% | Shares |
| JANE STREET GROUP, LLC | $1,821 | 24,274 | 0.63% | Shares |
| Limestone Investment Advisors LP | $1,692 | 22,562 | 0.59% | Shares |
| GTS SECURITIES LLC | $1,570 | 20,929 | 0.54% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,317 | 17,562 | 0.46% | Shares |
| WOLVERINE ASSET MANAGEMENT LLC | $1,048 | 13,976 | 0.36% | Shares |
| UBS Group AG | $338 | 4,507 | 0.12% | Shares |
| DUPONT CAPITAL MANAGEMENT CORP | $318 | 6,250 | 0.11% | Shares |
| HGC Investment Management Inc. | $94 | 1,250 | 0.03% | Shares |
| FLOW TRADERS U.S. LLC | $1 | 13,110 | 0.00% | Shares |
| Virtu Financial LLC | $1 | 10,805 | 0.00% | Shares |
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Valetudo Therapeutics LLC, Chris Kim | July 14, 2026 | 14.30% | Amendment | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 14, 2026